# A Safety and Efficacy Study of Xolair in Peanut Allergy

> **NCT00086606** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 150 (—)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** Xolair (omalizumab)

## Key facts

- **NCT ID:** NCT00086606
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 150 (—)
- **Last updated:** 2013-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086606, "A Safety and Efficacy Study of Xolair in Peanut Allergy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00086606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*